Table 1.
Characteristics of the 91 lesions according to mutation status
| Characteristic | ATMwtBRCAwt (n=46) | ATMmtBRCAwt (n=8) | ATMwtBRCAmt (n=27) | ATMmtBRCAmt (n=10) | p-value |
|---|---|---|---|---|---|
| Age (yr) | 56 (28–72) | 46 (39–57) | 55 (36–71) | 46 (26–66) | 0.023 |
| Sex | |||||
| Male | 19 (41.3) | 6 (75.0) | 10 (37.0) | 3 (30.0) | 0.238 |
| Female | 27 (58.7) | 2 (25.0) | 17 (63.0) | 7 (70.0) | |
| Primary site | |||||
| Breast | 1 (2.2) | 1 (12.5) | 2 (7.4) | 2 (20.0) | 0.004 |
| Lung | 18 (39.1) | 0 | (10 (37.0) | 1 (10.0) | |
| Gastrointestinal | 18 (39.1) | 3 (37.5) | 8 (29.6) | 4 (40.0) | |
| Genitourinary | 9 (19.6) | 1 (12.5) | 5 (18.5) | 3 (30.0) | |
| Skin | 0 | 0 | 2 (7.4) | 0 | |
| Unknown | 0 | 3 (37.5) | 0 | 0 | |
| Disease extent | |||||
| Metastatic | 42 (91.3) | 8 (100) | 26 (96.3) | 10 (100) | 0.885 |
| Localized | 4 (8.7) | 0 | 1 (3.7) | 0 | |
| Radiosensitivity | |||||
| Sensitive | 28 (60.9) | 2 (25.0) | 17 (63.0) | 6 (60.0) | 0.286 |
| Resistant | 18 (39.1) | 6 (75.0) | 10 (37.0) | 4 (40.0) | |
| Radiotherapy site | |||||
| Brain | 11 (23.9) | 0 | 6 (22.2) | 1 (10.0) | 0.351 |
| Lymph node | 12 (26.1) | 4 (50.0) | 5 (18.5) | 4 (40.0) | |
| Bone | 7 (15.2) | 3 (37.5) | 8 (29.6) | 0 | |
| Lung | 10 (21.7) | 2 (25.0) | 3 (11.1) | 1 (10.0) | |
| Liver | 2 (4.3) | 0 | 3 (11.1) | 1 (10.0) | |
| Others | 4 (8.7) | 0 | 3 (11.1) | 3 (30.0) | |
| Pre-RT chemotherapy | |||||
| Cytotoxic chemo | 35 (76.1) | 8 (100) | 19 (70.4) | 7 (70.0) | 0.484 |
| Target agents | 5 (10.9) | 0 | 5 (18.5) | 3 (30.0) | |
| None | 6 (13.0) | 0 | 3 (11.1) | 0 | |
| Site of NGS performed | |||||
| Primary | 30 (65.2) | 2 (25.0) | 17 (63.0) | 4 (40.0) | 0.111 |
| Metastatic | 16 (34.8) | 6 (75.0) | 10 (27.0) | 6 (60.0) | |
| RT site and sequenced site matched | |||||
| No | 37 (80.4) | 7 (87.5) | 24 (88.9) | 9 (90.0) | 0.826 |
| Yes | 9 (19.6) | 1 (12.5) | 3 (11.1) | 1 (10.0) | |
| Type of RT a) | |||||
| Conventionally fractionated | 12 (26.1) | 1 (12.5) | 3 (11.1) | 5 (50.0) | 0.122 |
| Hypofractionated | 28 (60.9) | 6 (75.0) | 23 (85.2) | 5 (50.0) | |
| SBRT | 6 (13.0) | 1 (12.5) | 1 (3.7) | 0 | |
| EQD2 (Gy) | |||||
| < 45 | 17 (37.0) | 2 (25.0) | 19 (70.4) | 4 (40.0) | 0.022 |
| ≥ 45 | 29 (63.0) | 6 (75.0) | 8 (29.6) | 6 (40.0) | |
Values are presented as median (range) or number (%). EQD2, equivalent dose in 2 Gy; NGS, next generation sequencing; RT, radiotherapy; SBRT, streotactic body radiotherapy.
a)
Conventional fractionation (1.8–2.4 Gy), hypofractionation (2.5–8 Gy), SBRT (≥ 10 Gy).